{In Vivo} summarizes the technologies of several medical companies founded within the last year. [Camitro Corp.] is developing computational models to predict ADME/PK properties of drug candidates. Researchers will be able to search for and purchase chemical compounds through [ChemNavigator.com]. Launched in September 1999, [Imetrx Inc.] is a cardiovascular interventional device company focused on locating and characterizing unstable coronary plaques that are responsible for atherosclerosis and acute cardiovascular events. Denmark's [NsGene A/S] is a joint venture of NeuroSearch A/S and the University of Lund. [Protein Pathways Inc.] aims to improve the speed and focus of drug development by determining functions for all genome-encoded proteins. [Trek Diagnostics Systems Inc.], a microbiology diagnostics testing company, was founded in January 1999 with the acquisition of the AccuMed International Inc.'s microbiology division.
Address: 4040 Campbell Ave.
Menlo Park, CA 94025
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
When it came to AI-related deals, the second quarter of 2025 was characterized by mostly modest financings.
The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.
Although intracerebral hemorrhage accounts for only 13% of all strokes, it is responsible for approximately 40% of stroke-related deaths. A Belgian biotech is looking in unusual places to rectify this situation, namely in a tick’s mouth.
